MedTrace Logo

European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients

NCT00217763 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 930

Last updated 2007-12-10

No results posted yet for this study

Summary

The purpose of this Phase 3 study is to evaluate the efficacy and safety of 3APS as an add-on therapy to most standard medication for Alzheimer's disease compared to placebo (inactive substance pill) in patients with mild to moderate Alzheimer's disease.

Conditions

Interventions

DRUG

3APS

Sponsors & Collaborators

  • Bellus Health Inc. - a GSK company

    lead INDUSTRY

Principal Investigators

  • Pr. Bruno Vellas · University Hospital Center, Toulouse

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2007-12-31

Countries

  • Belgium
  • France
  • Germany
  • Italy
  • Netherlands
  • Poland
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00217763 on ClinicalTrials.gov